Zhenfang Du

2.0k total citations · 1 hit paper
34 papers, 1.3k citations indexed

About

Zhenfang Du is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Zhenfang Du has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Zhenfang Du's work include Lung Cancer Treatments and Mutations (7 papers), Cancer-related gene regulation (5 papers) and Epigenetics and DNA Methylation (5 papers). Zhenfang Du is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer-related gene regulation (5 papers) and Epigenetics and DNA Methylation (5 papers). Zhenfang Du collaborates with scholars based in China, United States and Hong Kong. Zhenfang Du's co-authors include Christine M. Lovly, Qian Tao, Lili Li, Anthony T.�C. Chan, Francis K.L. Chan, Wai‐Yee Chan, Tony Mok, Richard F. Ambinder, Xianning Zhang and Yunkai Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Zhenfang Du

33 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of receptor tyrosine kinase activation in cancer

2018 707 citations Zhenfang Du, Christine M. Lovly profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhenfang Du China	15	776	404	279	227	122	34	1.3k
Beverly L. Falcón United States	16	804 1.0×	435 1.1×	216 0.8×	339 1.5×	126 1.0×	34	1.4k
Marion Wiesmann Switzerland	12	980 1.3×	477 1.2×	353 1.3×	166 0.7×	129 1.1×	20	1.6k
Mei Dong China	18	1.2k 1.6×	539 1.3×	159 0.6×	332 1.5×	159 1.3×	36	1.7k
Dongwei Zhang United States	16	589 0.8×	733 1.8×	284 1.0×	281 1.2×	80 0.7×	64	1.5k
Yuji Basaki Japan	20	1.1k 1.4×	540 1.3×	295 1.1×	214 0.9×	218 1.8×	27	1.5k
Francesco Merolla Italy	25	845 1.1×	486 1.2×	247 0.9×	209 0.9×	87 0.7×	66	1.3k
John S. Yordy United States	18	788 1.0×	605 1.5×	346 1.2×	353 1.6×	69 0.6×	32	1.5k
Todd R. Palmby United States	18	927 1.2×	541 1.3×	355 1.3×	179 0.8×	88 0.7×	19	1.6k
Cataldo Bianco Italy	24	757 1.0×	765 1.9×	427 1.5×	252 1.1×	110 0.9×	37	1.5k
Yongchang Shi United States	7	578 0.7×	535 1.3×	447 1.6×	211 0.9×	209 1.7×	9	1.3k

Countries citing papers authored by Zhenfang Du

Since Specialization

Citations

This map shows the geographic impact of Zhenfang Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenfang Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenfang Du more than expected).

Fields of papers citing papers by Zhenfang Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenfang Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenfang Du. The network helps show where Zhenfang Du may publish in the future.

Co-authorship network of co-authors of Zhenfang Du

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenfang Du. A scholar is included among the top collaborators of Zhenfang Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenfang Du. Zhenfang Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Du, Zhenfang, Yue Liu, Yang Zou, et al.. (2025). Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates. 82. 101266–101266. 5 indexed citations

Westover, David, Yue Liu, Xingyue Wang, et al.. (2024). Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer. Journal of Translational Medicine. 22(1). 565–565. 19 indexed citations

Brown, Benjamin P., Yunkai Zhang, Yingjun Yan, et al.. (2022). Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proceedings of the National Academy of Sciences. 119(30). e2206588119–e2206588119. 16 indexed citations

Du, Zhenfang, Benjamin P. Brown, Donna C. Ferguson, et al.. (2021). Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications. 12(1). 1382–1382. 49 indexed citations

Brown, Benjamin P., Yunkai Zhang, David Westover, et al.. (2019). On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clinical Cancer Research. 25(11). 3341–3351. 76 indexed citations

Zhang, Hui, Qingsong Ye, Zhenfang Du, et al.. (2018). MiR-148b-3p inhibits renal carcinoma cell growth and pro-angiogenic phenotype of endothelial cell potentially by modulating FGF2. Biomedicine & Pharmacotherapy. 107. 359–367. 30 indexed citations

Du, Zhenfang, et al.. (2017). Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing. Journal of Biosciences. 42(2). 209–218. 5 indexed citations

Du, Zhenfang, Jean‐Nicolas Gallant, Jonathan H. Sheehan, Jens Meiler, & Christine M. Lovly. (2017). Intramolecular Dimerization of EGFR Kinase Domain Duplication as a Novel Activation Mechanism. Journal of Thoracic Oncology. 12(8). S1536–S1536. 1 indexed citations

Li, Lili, Chen Li, Zhenfang Du, et al.. (2016). Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Scientific Reports. 6(1). 26591–26591. 103 indexed citations

10.

Shi, Peiliang, Xiaoling Chen, Yanfang Wang, et al.. (2016). A Small Indel Mutant Mouse Model of Epidermolytic Palmoplantar Keratoderma and Its Application to Mutant-specific shRNA Therapy. Molecular Therapy — Nucleic Acids. 5. e299–e299. 11 indexed citations

11.

Wei, Wenbin, et al.. (2014). Whole exome sequencing implicates PTCH1 and COL17A1 genes in ossification of the posterior longitudinal ligament of the cervical spine in Chinese patients. Genetics and Molecular Research. 13(1). 1794–1804. 19 indexed citations

12.

Du, Zhenfang, et al.. (2014). Adenovirus-mediated NDRG2 inhibits the proliferation of human renal cell carcinoma cell line OS-RC-2 in vitro. Asian Pacific Journal of Tropical Medicine. 7(11). 873–878. 2 indexed citations

13.

Qi, Xiao-Ping, Wenting Liu, Yun Dai, et al.. (2013). p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees. Molecular Medicine Reports. 8(3). 799–805. 6 indexed citations

14.

Du, Zhenfang, Chenming Xu, Yan Zhao, et al.. (2012). Two novel de novo mutations of KRT6A and KRT16 genes in two Chinese pachyonychia congenita pedigrees with fissured tongue or diffuse plantar keratoderma. European Journal of Dermatology. 22(4). 476–480. 5 indexed citations

15.

Chen, Xiaoling, Yan Zhao, Haiping Ke, et al.. (2012). Detection of somatic and germline mosaicism for the LAMP2 gene mutation c.808dupG in a Chinese family with Danon disease. Gene. 507(2). 174–176. 11 indexed citations

16.

Qi, Xiao-Ping, Xiaoling Chen, Zhenfang Du, et al.. (2012). RET Proto-Oncogene Genetic Screening of Families with Multiple Endocrine Neoplasia Type 2 Optimizes Diagnostic and Clinical Management in China. Thyroid. 22(12). 1257–1265. 22 indexed citations

17.

Du, Zhenfang, Wei Wei, Yifan Wang, et al.. (2011). A novel mutation within the 2B rod domain of keratin 9 in a Chinese pedigree with epidermolytic palmoplantar keratoderma combined with knuckle pads and camptodactyly. European Journal of Dermatology. 21(5). 675–679. 14 indexed citations

18.

Qi, Xiao-Ping, et al.. (2011). Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma. Familial Cancer. 11(1). 131–136. 5 indexed citations

19.

Qi, Xiao-Ping, Zhenfang Du, Jun Fei, et al.. (2011). RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2A/Familial Medullary Thyroid Carcinoma Family. PLoS ONE. 6(5). e20353–e20353. 37 indexed citations

20.

Xu, Chenming, et al.. (2010). A c.1363C>T (p.R455X) Nonsense Mutation of RB1 Gene in a Southern Chinese Retinoblastoma Pedigree. Genetic Testing and Molecular Biomarkers. 14(2). 193–196. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact